Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast.

ABSTRACT: In the EV-302/KEYNOTE-A39 trial (NCT04223856), enfortumab vedotin + pembrolizumab (EV + P) became the first treatment in decades to demonstrate significant survival benefit compared with platinum-based chemotherapy in the first-line setting for patients with locally advanced or metastatic urothelial cancer. The safety profile of EV + P in EV-302/KEYNOTE-A39 was consistent with previous clinical studies and with the expected safety profiles of each agent alone; however, real-world experience in the management of adverse events (AEs) resulting from treatment with EV + P in patients with locally advanced or metastatic urothelial cancer is still evolving. Historically, healthcare professionals have been familiar with the management of EV and pembrolizumab as monotherapies, with guidance availa

SUBMITTER: Powles T 

PROVIDER: S-EPMC12647415 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature